Categories
Tag: CAR T-cell
Implementing Bispecific Treatments
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA. In this segment, Mahmoudjafari and Mancini discuss the implementation of step-up dosing for bispecific therapies in lymphoma patients. Mancini details the multifaceted approach at his…
Cost and Benefit: Lisocabtagene Maraleucel is Cost Effective as Second-line Treatment for Lymphoma
Lisocabtagene maraleucel (liso-cel; Breyanzi®; Bristol-Myers Squibb), a CD19-directed genetically modified autologous T-cell immunotherapy, also known as chimeric antigen receptor (CAR) T-cell therapy, is a cost effective second line treatment for relapsed and refractory diffuse large B-cell lymphoma (r/r DLBCL). This conclusion is based on results from a study published in…
How MRD Testing Can Help
MRD testing is incredibly valuable in informing clinical decision-making in the treatment of lymphoid malignancies, and its adoption by all oncologists is crucial in the era of precision medicine. During my 10 plus years of practicing medicine, I have seen the blood cancer treatment landscape transform, as the development of…
ASH 2023: Lymphoma Studies May Inform Practice
Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…
ASH 2023: CAR T-Cell Therapy Safe, Effective for High-Risk DLBCL Patients
ASH 2023: CAR T-Cell Therapy Safe, Effective for High-Risk DLBCL Patients | PracticeUpdate …
Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242. Article CAS PubMed Google Scholar Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie…
Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL
T-cell engaging therapeutic approaches have significantly changed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in recent years. “They are, by a wide margin, the most impactful new therapies for all B-cell lymphomas, but especially DLBCL, in the last 40 years, if not ever,” said Joshua…
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair
Khan, S. et al. Role of recombinant DNA technology to improve life. Int. J. Genomics Proteomics 2016, 2405954 (2016). Google Scholar Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018). Article CAS PubMed Google…
Complete Interim Response, SCT Beats CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
CRS Occurs in More Than Half of CAR-T Therapy Recipients
Real-world data suggested that cytokine release syndrome (CRS) among chimeric antigen receptor (CAR) T-cell therapy recipients with hematologic malignancy occurred among 56.2% to 71.7% of patients, according to results of a study that were presented at the ASH Annual Meeting 2023. “CRS is a potentially life threatening and supraphysiological response…
NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies
NX-1607 in DLBCL | Image Credit: © freshidea – stock.adobe.com The phase 1a/1b NX-1607-101 trial (NCT05107674) will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma (DLBCL), according to a poster that was presented during the 2023 ASH Annual Meeting. The dose-escalation portion of…
Recent Developments in Lymphoma Treatment
Combination Therapy Shows Promising Results In a recent Phase 1/2 trial, a combination of mosunetuzumab, a CD20-CD3 bispecific antibody, and polatuzumab vedotin, an anti-CD79B antibody-drug conjugate, demonstrated a significant overall response rate of 59.2% in patients with relapsed or refractory large B Cell lymphoma. This study, presented at the ASH23…
Comprehensive Review of Small Interfering RNAs (siRNAs)
Introduction Cancer, also called malignancy, is a group of diseases caused by the rapid multiplication and spread of malignant cells.1,2 According to statistics from the National Cancer Center, more than 100 types of cancer have been identified.3 The ability of malignant tumor cells to metastasize via the blood-lymphatic system and…
The future of cancer care: a path toward personalized treatment
The biological complexity of cancer is individual to each patient, and it presents many roadblocks on the path toward optimal treatments. However, developments in DNA technologies and advanced imaging tools have greatly informed clinicians and researchers on ways to develop methods for precision care. Morgridge biomedical imaging investigator Dr. Melissa Skala and…
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…
City of Hope Scientists Present Promising New Research at American Society of Hematology Annual Meeting
This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Breadcrumb Trail Links PMN Press Releases Business Wire News Releases Author of the…
Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So
Just a few years ago, chimeric antigen receptor (CAR) T-cell therapy was brand new, offering a novel solution for populations of patients who were short on options and typically faced grim prognoses. But this weekend at the American Society of Hematology Annual Meeting and Exposition, a presentation saw experts in…
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…
Khan Discusses Third-Line Novel Treatment Approaches for R/R DLBCL
Cyrus M. Khan, MD (MODERATOR) Hematologist Division of Hematology and Cellular Therapy West Penn Hospital of Allegheny Health Network Pittsburgh, PA EVENT REGION Pennsylvania PARTICIPANT LIST Haixia Qin, MD, PhD | Simi Rai, MD | Naeem Latif, MD | Alexander Barsouk, MD | Gurprataap Sanhu, MD | Hayman Salib, MD…
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
By The ASCO Post StaffPosted: 12/6/2023 9:39:00 AM Last Updated: 12/6/2023 10:33:56 AM Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al…
Cost-Effectiveness and Health Care Spending
Chimeric antigen receptor T-cell (CAR-T) therapies, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), have been hailed as breakthroughs in the treatment of various cancers. However, a recent study published in the Annals of Internal Medicine has raised questions about their cost-effectiveness for patients with diffuse large B-cell lymphoma…
FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia
An investigational new drug application was cleared by the FDA for CT071 in this indication. CT071 is an autologous chimeric antigen receptor (CAR) T-cell therapy candidate being developed for the treatment of multiple myeloma (MM) and primary plasma cell leukemia (PCL). A phase 1 trial evaluating CT071 is ongoing in…
Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM
Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Attend In-Person or Virtually for an exciting and informative event, Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care, happening at the San Diego Convention Center on Friday, December 8, 2023, 3:00…
What does it mean for oncology and beyond?
Chimeric antigen receptor (CAR) T-cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR T-cell…
Ny tantaran’i Kim – DLBCL & CAR T-cell therapy
Tamin’ny Septambra 2020, i Kim dia voan’ny Lymphoma B-Cell Diffuse Large. Indrisy anefa fa tsy namaly ny fitsaboana tamin’ny voalohany i Kim. Ny ekipany ao amin’ny Hopitaly PA any Brisbane dia afaka nanondro azy ho any amin’ny ekipa mpitrandraka ao amin’ny RBWH mba hidirana amin’ny fitsaboana T-cell CAR vaovao. Hatramin’ny…
Physicians Consider Loncastuximab for Older Patients With R/R DLBCL
Paolo Strati, MD Assistant Professor Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, TX CASE SUMMARY: A 73-year-old woman presented with fever, headaches, and 7-lb unintentional weight loss. She was married with 2 grown children who live in other states and the primary caretaker for her mother…
Gene Editing Market Size Worth USD 35.84 Billion in 2032 |
Vancouver, Nov. 30, 2023 (GLOBE NEWSWIRE) — The global gene editing market size was USD 6.11 Billion in 2021 and is expected to register a revenue CAGR of 17.5% during the forecast period. The global gene editing market is experiencing significant growth, driven by advancements in technology and a surge…
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
CASE A 67-year-old man presented with fatigue, back pain, and lymphadenopathy. Medical history: Hypertension, well controlled with medication Physical exam: Left posterior cervical, 1.5-cm node; right anterior cervical node, 2.5-cm; left supraclavicular node, 2.0-cm. PET-CT scan: multiple enlarged mesenteric and retroperitoneal nodes, largest measuring 5.3 x 3.1 cm Bone marrow biopsy was…
CTLA4 Deletion Boosts CAR T-Cell Efficacy
Cancer Cell Image: © sipgus – stock.adobe.com CTLA4 deletion shows promise as a strategy to overcome T-cell dysfunction and may increase the efficacy of chimeric antigen receptor (CAR) T-cell therapy.1 According to findings published in Immunity, CTLA4 deletion in CAR T cells improves the antitumor efficacy and surface of CAR…
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer
Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article CAS PubMed PubMed Central Google Scholar Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article CAS PubMed Google Scholar Lawrence…
Personalized medicine: “Tyranny of the gene”
Dr Priya Hays, Ph.D., CEO/Science Writer at Hays Documentation Specialists, LLC, responds to “Tyranny of the Gene.” Is personalized medicine a threat to public health? Not really, but yes, it’s an argument for price controls and perhaps more regulations; we hear Tyranny of the Gene: Personalized Medicine’s Threat to Public…
Genome Editing Market revenue to hit USD 69.6 Billion by
New York, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global genome editing market size is slated to expand at ~21.1% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 69.6 billion by the end of 2036, up from a revenue of ~USD 7 billion…
Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm
Although progress in the development of new treatment regimens for the management of patients with diffuse large B-cell lymphoma (DLBCL) has been relatively slow overall, recent developments in both the frontline and relapsed/refractory spaces have stirred optimism amongst clinicians in the field, according to a presentation given by Gilles A. Salles,…
Celyad Oncology reports third quarter 2023 financial
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic Acids Five posters were presented at the 38th SITC Annual Meeting and two posters were presented at the 4th ICLE conference, with further developments in…
Latent human herpesvirus 6 is reactivated in CAR T cells
Spanjaart, A. M., van der Valk, F. M., van Rooijen, G., Brouwer, M. C. & Kersten, M. J. Confused about confusion. N. Engl. J. Med. 386, 80–87 (2022). Article PubMed Google Scholar Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphoma….
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer | Military Medical Research
Zhu J, Ke Y, Liu Q, Yang J, Liu F, Xu R, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022;13(1):7466. Article CAS PubMed PubMed Central Google Scholar Evans ER, Bugga P, Asthana V, Drezek R. Metallic nanoparticles for cancer…
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. Publication , Journal Article Liang, Y; Liu, H; Lu, Z; Lei, W; Zhang, C; Li, P; Liang, A; Young, KH; Qian, W Published in: J Hematol Oncol CD19-targeted chimeric antigen…
CAR T-cell therapy now covered by NHI for two-year period
Taipei, Nov. 3 (CNA) Patients with two types of cancers who get CAR T-cell treatment costing millions of Taiwan dollars will now be covered by Taiwan’s national health insurance (NHI) system, as the National Health Insurance Administration (NHIA) indicated in October. Starting Nov. 1, the treatment is covered under the…
Tazemetostat/Lenalidomide/Rituximab Regimen Enters Phase 3 Research in R/R Follicular Lymphoma
The addition of tazemetostat (Tazverik) to standard lenalidomide (Revlimid) plus rituximab (Rituxan) has elicited early signals of efficacy in patients with relapsed/refractory follicular lymphoma (FL) in the safety run-in portion of the phase 1b/3 SYMPHONY-1 trial (NCT04224493), prompting the continuation of this research in the phase 3 portion of the…
[Pathobiology and its clinical relevance in diffuse large B-cell lymphoma]
doi: 10.11406/rinketsu.64.1026. [Article in Japanese] Affiliations Expand Affiliation 1 Center for Comprehensive Genomic Medicine, Okayama University Hospital. Item in Clipboard [Article in Japanese] Daisuke Ennishi. Rinsho Ketsueki. 2023. Show details Display options Display options Format AbstractPubMedPMID doi: 10.11406/rinketsu.64.1026. Affiliation 1 Center for Comprehensive Genomic Medicine, Okayama University Hospital. Item in…
Phase 2 GUIDANCE Trial of R-CHOP-X Meets Primary End Point in DLBCL
Red blood cells: © vipman4 – stock.adobe.com Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone or combined with targeted agents (R-CHOP-X) demonstrated efficacy and safety in patients with newly diagnosed, intermediate-risk, or high-risk diffuse large B-cell lymphoma (DLBCL), according to findings published in Cancer Cell.1 In the randomized, phase…
Beam Therapeutics lays off staff, adjusts research focus
Gene editing company Beam Therapeutics became the latest biotech to announce staff layoffs Oct. 19. The firm plans to lose 100 employees–20% of its workforce. The company, based in Cambridge, Massachusetts, also says it will cut back on its pipeline. The cost savings from these changes will keep the lights…
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article CAS PubMed Google Scholar Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….
Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL
At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab (Monjuvi) and lenalidomide (Revlimid) fits in as physicians continue to see successes with chimeric antigen receptor T-cell therapy….
Treating Refractory and Relapsed Diffuse Large B-Cell Lymphoma
Updated on October 24, 2023 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma. DLBCL begins with mutations to B cells, a type of immune cell that produces antibodies that protect the body from infections, toxins, and parasites. DLBCL is considered an aggressive cancer. It…
Axicabtagene Ciloleucel Works in Refractory DLBCL
Axicabtagene Ciloleucel (Yescarta®), developed by Kite, appears to outperform the effectiveness of epcoritamab and gllofitamab in the treatment of refractory diffuse large B-cell lymphoma (DLCBL), according to a recently published press release. Approximately 40% of patients with DLBCL are refractory or experience relapse after receiving treatment with standard-of-care chemotherapy with…
Use of CAR-T Therapy Limited in Older Patients With DLBCL, Despite Efficacy
Patients older than age 65 with relapsed/refractory diffuse larger B-cell lymphoma (DLBCL) treated with chimeric antigen receptor (CAR) T-cell therapy experienced long-term remission, according to the results of a retrospective study. However, the use of CAR-T therapy was limited. “This study indicated an unmet need for more accessible, effective, and…
CAR T-cell therapy safe for older patients with relapsed or refractory DLBCL
Key clinical point: Chimeric antigen receptor (CAR) T-cell therapy is effective for and can be safely administered to older patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) despite an increased infection rate. Major finding: At a median follow-up of 16.3 months, the objective response rate was 67%. Median…
EX103 Yields Preliminary Activity, Tolerability in R/R Non-Hodgkin Lymphoma
“EX103 induces rapid and deep responses in heavily pretreated patients with B-cell NHL across different subtypes,” according to Mingyuan Sun, MD. Investigators reported favorable safety and preliminary anti-tumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) treated with EX103, according to findings from a phase 1 trial…
Server SDMS Use at Bristol Myers Squibb
This presentation will discuss how LabKey Server is used as a data engine to integrate and harmonize clinical, manufacturing and translational data from CAR T-Cell clinical trials at Bristol Myers Squib. The aim is to accelerate exploratory correlative analysis, along with other use cases such as facilitating electronic data capture…
Study of Tisagenlecleucel in DLBCL Shows Similar Responses to Clinical Trial
Tisagenlecleucel (Kymriah®) treatment results in a response in roughly half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a single-center, retrospective analysis.s The best overall response rate (ORR) observed during the analysis was 52%, which included a complete response (CR) in 32% of patients and…
Advances in Polatuzumab Vedotin-PIIQ Therapy
Introduction Between 30 to 40% of non-Hodgkin lymphoma cases globally are diffuse B-cell lymphoma (DLBCL), the most prevalent disease. Patients often have a rapidly expanding nodal or extranodal tumor mass in one or more locations.1 The concept of “high-grade B-cell lymphoma” has historically been used to refer to B-cell lymphomas…
NHI to cover CAR T-cell therapy for two types of cancer from November
Taipei, Oct. 16 (CNA) From November, patients with two types of cancers will be eligible to receive CAR T-cell treatment under Taiwan’s National Health Insurance (NHI) system, the National Health Insurance Administration (NHIA) said Sunday. The treatment, which takes immune T cells and modifies them with chimeric antigen receptors, or…
DLBCL Patients – What is CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that helps the patient’s T-cells become efficient at destroying the cancer. For some DLBCL patients, it has cured their cancer. The CAR T-cell therapy called Yescarta (axicabtagene ciloleucel) is FDA-approved for DLBCL patients as: A second line of therapy if…
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
Matthew A. Lunning, DO (MODERATOR) Assistant Vice Chancellor of Clinical Research Associate Vice Chair of Research Department of Internal Medicine Associate Professor, Division of Oncology and Hematology University of Nebraska Medical Center Omaha, NE EVENT REGION Minnesota and Nebraska PARTICIPANT LIST Dahlia H. Elkadi, MBBCh | Kurt Demel, MD |…
Bridging RT Before CAR T-Cell Therapy Can Benefit Patients With R/R DLBCL
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) may benefit from bridging radiation therapy (bRT) ahead of receiving chimeric antigen receptor (CAR) T-cell therapy, according to an abstract presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting and published in the International Journal of Radiation Oncology,…
Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells
Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). Article CAS PubMed PubMed Central Google Scholar Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a…
Cytokine Release Syndrome Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market
PRESS RELEASE Published October 4, 2023 “Cytokine Release Syndrome Market” DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain,…
Odronextamab Granted Priority Review for Rel/Ref FL, DLBCL
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) whose disease has progressed after at least 2 prior systemic therapies.1 Odronextamab is a CD20 x CD3 bispecific…
CAR T-Cell Therapy: Promising Treatments in Development for DLBCL
There have been several recent developments in the treatment of B-cell lymphoma; however, one of the most significant advances has been the development of chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy is a type of personalized immunotherapy that can help cure some people with aggressive non-Hodgkin lymphoma (NHL),…
Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
Mehdi H. Hamadani, MD Professor of Internal Medicine Division of Hematology & Oncology Medical College of Wisconsin Milwaukee, WI TARGETED ONCOLOGY: What bispecific T-cell engagers are available for use in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)? MEDHI H. HAMADANI, MD: There are 2 bispecific agents recently approved in…
Odronextamab Receives FDA Priority Review in R/R DLBCL/Follicular Lymphoma
The European Medicines Agency accepted a marketing authorization application for odronextamab for relapsed/refractory follicular lymphoma or DLBCL in August 2023. The FDA has granted priority review to a biologics license application (BLA) for odronextamab as a treatment for patients diagnosed with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL)…
FDA Grants Priority Review to Odronextamab in Relapsed/Refractory Follicular Lymphoma or DLBCL
The FDA has granted priority review to the biologics license application (BLA) seeking the approval of odronextamab (REGN1979) for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have progressed after at least 2 prior systemic therapies.1 The BLA is supported by…
Innovative strategies of reprograming immune system cells
Introduction Cancer is well characterized by genomic instability resulting in structural alterations that build up with tumor progression.1,2 A subpopulation of undifferentiated cancer cells, known as cancer stem cells (CSCs) are found within the tumor bulk. These cells are responsible for cancer initiation, recurrence and show therapeutic resistance and these…
Epcoritamab Wins European and Japanese Approval for Select Types of R/R LBCL
The European Commission (EC) has granted conditional marketing authorization to epcoritamab-bysp (Tepkinly) for use as a single agent in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic treatment.1 Additionally, Japan’s Ministry of Health, Labour, and Welfare has approved the agent…
Imugene stacks up $53.2m for cancer-fighting mission
Cancer fighter Imugene has positioned itself as one of the most cashed-up med-tech companies on the ASX after raising a further $18.2 million from a share placement plan (SPP) to add to a previous $35 million placement. Management revealed last month that it had shored up its $35 million placement…
Sborov and Participants Discuss Later-Line Treatment in Multiple Myeloma
Douglas W. Sborov, MD, MS (MODERATOR) Associate Professor, Division of Hematology and Hematologic Malignancies Department of Internal Medicine University of Utah School of Medicine Huntsman Cancer Institute Salt Lake City, UT EVENT REGION Arizona, Colorado, New Mexico, Utah PARTICIPANT LIST Christopher Chen, MD | Muhammad Anas Tarajki, MD | Darshil…
‘AI will play major role in drug discovery, development’: Dr Jame Abraham
There are theories about why Hippocrates, the father of medicine, named a cluster of abnormal cells karkinos (Greek for crab). Was it because the tumour felt hard as a rock, reminding him of the crab’s shell? Or, was it because of the stubborn nature of the disease, quite like how…
Chemosensitivity helps predict survival outcomes after CAR T-cell therapy for DLBCL
Key clinical point: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who respond to salvage chemotherapy immediately before chimeric antigen receptor (CAR) T-cell therapy administration have better survival outcomes than those with stable or progressive disease, irrespective of the administration timing. Major finding: Patients who did vs did…
Phillips Discusses Treatment Options for Early-Relapsed DLBCL
Tycel J. Phillips, MD (MODERATOR) Associate Professor, Division of Lymphoma Department of Hematology & Hematopoietic Cell Transplantation City of Hope Duarte, CA EVENT REGION Maryland; Virginia; Washington, DC PARTICIPANT LIST Xinting Fu, MD | Andrew Pham, MD | David Shin, MD | Sharon Yee, MD | Albert Dekker, MD |…
Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL
This article was originally published by OncLive. Subcutaneous epcoritamab-bysp (Epkinly) produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial (NCT03625037) presented during the 2023 SOHO…
New Radiomic Signature May Predict Therapy Response in DLBCL
A novel radiomics signature could predict treatment response in patients with diffuse large B-cell lymphoma (DLBCL), according to a study recently published in eJHaem. “This model outperformed conventional PET parameters and showed an independent predictive value after adjusting for well-known clinical factors,” the authors highlighted. Read more about DLBCL prognosis This…
Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL
Mehdi H. Hamadani, MD (Moderator) Professor of Internal Medicine Division of Hematology & Oncology Medical College of Wisconsin Milwaukee, WI DISCUSSION QUESTIONS If a patient relapses after or refractory to chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL), do you have a preferred regimen? What factors influence…
Axi-Cel Yields High Responses in R/R High-Risk Large B-Cell Lymphoma
“ALYCANTE is the first study to assess [axi-cel] as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population,” according to Roch Houot, professor and head of the Haematology Department at University Hospital of Rennes, France. Treatment with axicabtagene…
Drug delivery systems for CRISPR-based genome editors
Li, Y., Glass, Z., Huang, M., Chen, Z. Y. & Xu, Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials 234, 119711 (2020). Article CAS PubMed PubMed Central Google Scholar Dong, W. & Kantor, B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR/Cas: current state and…
Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL
A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in a study published in eJHaem. CAR T-cell therapy is an established third-line R/R…
Novel Therapies Are Paving the Way to Better Patient Outcomes
This World Lymphoma Awareness Day, it’s important to remember that while the disease is increasingly more common, multiple novel therapies are available to better combat this disease. According to the National Institute of Health Surveillance, Epidemiology, and End Results (SEER) program, the estimated number of new cases of non-Hodgkin lymphoma…
Novel CAR T-Cell Therapy Shows Promise for Patients With DLBCL
Novel therapy could yield durable benefits with an acceptable safety profile for patients with diffuse large B cell lymphoma (DLBCL), according to a scientific poster presented at the Society Hematologic Oncology 11th Annual Meeting and published in Clinical Lymphoma, Myeloma & Leukemia. “Rapcabtagene autoleucel, a next-generation, autologous CD19-directed CAR T-cell…
Chaos of DLBCL Treatments Needs Organization
It remains to be seen how various therapies for diffuse large B-cell lymphoma will be used and in what order to treat patients, explained Matthew Lunning, DO, FACP, associate professor, Division of Hematology/Oncology, University of Nebraska Medical Center. In an interview with The American Journal of Managed Care® (AJMC®) he…
High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody
HOUSTON — More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a pivotal trial. Overall, 63% of 157 patients responded, including 39% who had complete responses. Responses by lymphoma subtype consisted of 61% of…
Subcutaneous Epcoritamab Induces Lasting Responses in R/R LBCL
Cells | Image Credit: abhijith3747 – www.stock.adobe.com In the phase 1/2 EPCORE NHL-1 trial (NCT03625037), treatment with subcutaneous epcoritamab-bysp (Epkinly) achieved deep and durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL). Further, patients who were complete responses had favorable long-term outcomes, according to updated data presented…
The New Algorithm for Second-Line Large B-Cell Lymphoma Treatment
New enhanced treatment options with prolonged overall survival are improving patient outcomes in diffuse large B-cell lymphoma (DLBCL), according to Jason Westin, MD, director of Lymphoma Clinical Research Program and section chief of Aggressive Lymphoma, Department of Lymphoma and Melanoma at The University of Texas MD Anderson Cancer Center in…
Dr Burke on Treatment Paradigm Shifts in Relapsed DLBCL
John Burke, MD, hematologist, medical oncologist, blood cancer specialist, Rocky Mountain Cancer Centers, discusses the evolution of the diffuse large B-cell lymphoma (DLBCL) treatment paradigm. One major evolution in the DLBCL therapeutic landscape has been the advent of CAR T-cell therapy, Burke says. The phase 3 ZUMA-7 trial (NCT03391466) showed…
What DLBCL Clinical Trials are Available to Me?
September 7, 2023 What Clinical Trials are Available to Me? Edited by:Katrina Villareal Experts and patients discuss the latest in diffuse large B-cell lymphoma (DLBCL). Dr. Josh Brody of Mount Sinai Hospital, clinical trial nurse navigator Crissy Kus of The Leukemia & Lymphoma Society, and DLBCL survivor Dr. Robyn Stacy-Humphries…
Chemosensitivity May Be Useful in Predicting Survival Outcomes in DLBCL
Chemosensitivity is still a key factor in predicting survival outcomes following chimeric antigen receptor (CAR T-cell) therapy in diffuse large B-cell lymphoma (DLBCL), according to a new study published in the journal Cancer Medicine. This is irrespective of the timing of the treatment administration. The study also showed that both…
DLBCL in Older Adults: Applying the Goldilocks Principle
Image Credit: David A Litman – www.stock.adobe.com It is commonly said that “all oncologists are geriatric oncologists,” and this is especially true for those who treat diffuse large B-cell lymphoma (DLBCL), which has a median age of diagnosis of 66 years, with over half of patients older than 65 years.1…
Improving Outcomes for Older Adults with Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) primarily affects older adults, with a median age of diagnosis of 66 years. However, outcomes for older adults with DLBCL are suboptimal compared to younger patients. The 5-year relative survival rate for older adults is 54.3%, while it is 78.4% for those younger than 55…
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology SA Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023 Celyad Oncology has received approximately EUR 9.8m in private placement commitments from historical shareholders Encouraging progress in multiplex shRNA platform development, which allows now targeting of up to four genes simultaneously, were presented at international…
Biotechnology Market is Expanding USD 3,995.22 Billion By 2032
According to Precedence Research, the global biotechnology market was valued at USD 1,224.31 billion in 2022 and is estimated to be worth around USD 3,995.22 billion by 2032, expanding at a healthy CAGR of 12.5% from 2023 to 2032. The global biotechnology market stands at the forefront of scientific innovation,…
Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides
Wagner, A., Regev, A. & Yosef, N. Revealing the vectors of cellular identity with single-cell genomics. Nat. Biotechnol. 34, 1145–1160 (2016). Article CAS PubMed PubMed Central Google Scholar Gehring, J., Hwee Park, J., Chen, S., Thomson, M. & Pachter, L. Highly multiplexed single-cell RNA-seq by DNA oligonucleotide tagging of cellular…
Mutations in Target Proteins Provide Fresh View of Multiple Myeloma Resistance to T-Cell Therapies
NEW YORK – Newly identified genomic alterations associated with relapse and resistance to targeted T-cell therapies in multiple myeloma patients may offer opportunities for tailoring treatment, according to a study published Thursday in Nature Medicine. A group of researchers from City of Hope, the University of Miami, the University of…
Barriers to CAR T-Cell Therapy for LBCL Challenge Physicians and Patients
Image credit: © Dr_Microbe via Adobe Stock THE FDA APPROVALS of chimeric antigen receptor (CAR) T-cell therapies in hematologic malignancies have moved these novel options into standard treatment algorithms for diseases including large B-cell lymphoma (LBCL). However, various obstacles prevent CAR T-cell therapies from being used to their full potential…
ASCO Reading Room | Manali Kamdar, MD, on Practical Considerations for Using CAR T-Cells for DLBCL
The advent of chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Upfront chemoimmunotherapy cures most patients with DLBCL, but approximately 30-40% will relapse. Although in some cases autologous stem-cell transplantation (ASCT) offers a second chance at a durable remission, patients…
Genomic Features May Contribute to Treatment Failure in Some DLBCL Cases
Several genomic factors appear to be associated with resistance to antiCD19 chimeric antigen receptor (CAR) T-cell (CAR-19) treatment in some patients with large B-cell lymphomas (LBCLs), including diffuse large B-cell lymphoma (DLBCL), according to a whole-genome sequencing (WGS) study published in the journal Blood. The WGS identified several pretreatment factors,…
EU’s EMA Accepts Application for Odronextamab in Follicular Lymphoma/DLBCL
“These positive pivotal phase 2 results investigating odronextamab in heavily pre-treated, relapsed/refractory follicular lymphoma patients showed deep and durable response—confirming earlier findings in this program—with the highest [CR] rates seen in this patient population to date,” according to Tae Min Kim, MD, PhD. The European Medicines Agency has accepted a…
CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine | DNA RNA and Cells
CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine Details Category: DNA RNA and Cells Published on Tuesday, 22 August 2023 10:54 Hits: 96 SHANGHAI, China and CAMBRIDGE, MA, USA I August 21, 2023 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused…
Imugene cashing up for cancer-crushing mission
Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate the immune system of cancer patients to help treat and eradicate tumours. The company recently entered into an agreement with Precision Biosciences to acquire a world-wide exclusive license for its off-the-shelf…
Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy
. 2023 Mar;102(3):597-601. doi: 10.1007/s00277-023-05088-7. Epub 2023 Jan 30. Affiliations Expand Affiliations 1 National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. 2 College of Art and Science, New York University, New York City, NY, USA. 3 National Clinical Research Center for…
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab, an investigational bispecific antibody manufactured by Regeneron Pharmaceuticals, for the treatment of adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) who have progressed after at least 2…
Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies
Raajit K. Rampal, MD, PhD Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents (HMAs) can lead to spleen and symptom burden reductions, according to Raajit K. Rampal, MD,…